ALLO Stock Summary and Trading Ideas (Allogene Therapeutics | NASDAQ:ALLO)

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Allogene Therapeutics trades on the NASDAQ stock market under the symbol ALLO.

As of February 6, 2026, ALLO stock price climbed to $1.69 with 3,334,748 million shares trading.

ALLO has a beta of 1.66, meaning it tends to be more sensitive to market movements. ALLO has a correlation of 0.10 to the broad based SPY ETF.

ALLO has a market cap of $379.79 million. This is considered a Small Cap stock.

Last quarter Allogene Therapeutics reported $0 in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-1,820 and exceeded earnings estimates by $.04.

In the last 3 years, ALLO traded as high as $7.76 and as low as $.86.

The top ETF exchange traded funds that ALLO belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ALLO has underperformed the market in the last year with a price return of +5.6% while the SPY ETF gained +15.1%. However, in the short term, ALLO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +61.0% vs +3.3% return in SPY. But in the last 2 weeks, ALLO shares have been beat by the market, returning -1.7% compared to an SPY return of +0.2%.

ALLO support price is $1.51 and resistance is $1.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALLO shares will trade within this expected range on the day.